IDO1 and glioblastoma: Because IDO1 metabolizes tryptophan into kynurenine, this strategy of using AMT PET to monitor therapeutic response with an IDO1 inhibitor serves as an example of a PET radiotracer “companion diagnostic” to targeted molecular therapy in GBM.